银杏叶提取物对鹌鹑高脂血症的影响

目的 :观察银杏提取物 (银杏总黄酮 50 %、银杏内酯 2 5 % ) (GBE)对鹌鹑高脂血症的影响。方法 :在高脂饲料喂饲鹌鹑 2周后 ,用药组再同时灌服GBE(2 0 ,40 ,80mg/kg·d) 4周后测定血脂水平。 结果 :小剂量组 (2 0mg/kg·d)能明显降低血清TC、LDL C(P <0 .0 1 ) ,降低TG(P <0 .0 5) ;中剂量组 (40mg/kg·d)和大剂量组 (80mg/kg·d)均能明显降低血清TC、TG、LDL C(P <0 .0 1 ) ,其中高剂量组同时可升高apoAI(P <0 .0 5) ,三个剂量组均可降低apoB(P <0 .0 1或 0 .0 5)和TC HDL C/HDL C比值 (P <0 .0 1 ) ,HDL C有升高的趋势。给予GBE后 ,可使肝重量系数明显减轻 (P <0 .0 1或 0 .0 5) ,脂肪空泡数明显减少。结论 :GBE具有明显的防治鹌鹑高脂血症和肝脂肪变性的作用     

茵陈提取物对SD大鼠高脂血症模型血脂水平和肝脂肪变的影响

目的：观察茵陈提取物对高脂血症大鼠血脂和肝脏脂肪变性程度的影响。方法：用高脂饲料复制SD大鼠高脂血症模型,观察茵陈提取物对造模大鼠血清总胆固醇（TC）和甘油三酯（TG）水平的影响,对造模大鼠肝脏脂肪变性和MDA含量和SOD活性的影响。结果：茵陈提取物6,3,1.5g/kg能有效降低高脂血症大鼠血清中TC、TG、LDLC的含量,升高血清中HDLC的含量,并具有不同程度减轻高脂血症大鼠肝脂肪变,降低肝脏MDA含量,提高SOD活性的作用。结论：茵陈提取物通过调整血脂,对高脂血症大鼠模型具有良好的降脂和减轻肝脂肪变的作用。     

复方水蛭胶囊对实验性高脂血症大鼠的防治研究

目的：观察复方水蛭胶囊对高脂血症大鼠血脂的调节作用。方法：将60只大鼠随机分为6组(除空白组外，其余5组均饲高脂饲料)，即空白组、模型组、阳性药对照组及复方水蛭胶囊高、中、低剂量组，观察28d。结果：用药各组均有明显降低TC、TG、LDL-C及升高HDL-C作用，以复方水蛭胶囊高剂量组为优。结论：复方水蛭胶囊有较好的调节血脂作用。     

复方银杏叶制剂对动物血脂影响的实验研究

目的 :观察复方银杏叶制剂对动物血脂的影响。方法 :建立实验性的高血脂模型 ,以复方银杏叶制剂饲喂大白兔 8周 ,观察并测定血清中的 TC、TG、HDL、LDL指标。结果 :复方 组、复方 组与模型组比较 ,TG、TC、LDL 降低 ,HDL升高 ,经统计学处理有高度显著性差异。结论 :复方银杏叶制剂有明显降低血脂的作用。     

油菜花粉提取物对高脂血症大鼠血脂的影响

目的:探讨油菜花粉提取物对高脂血症大鼠血脂的影响.方法:利用脂肪乳剂灌胃造成实验性高脂血症大鼠模型,血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C),按酶法测定.结果:油菜花粉提取物8、4和2ml/kg均能降低高脂血症大鼠血清TC、TG、LDL-C,升高DHL-C,使TC/HDL-C比值明显降低.结论:油菜花粉提取物有调血脂作用.     

沙棘叶提取物对高脂血症大鼠的调血脂作用

目的:研究沙棘叶提取物对实验性高脂血症大鼠的调脂作用。方法:将已造模好的实验性高脂血症大鼠分别ig 500,400和200 mg/kg沙棘叶提取物30d,称体重,取血测血清中的胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)。结果:实验动物经用药后血脂水平基本恢复到正常,其值与正常对照组比较无显著差异。结论:沙棘叶提取物能调节实验性高脂血症大鼠血酯、控制体重的作用。     

脂汰清对实验性高脂血症兔降血脂机制研究

目的：探讨脂汰清对实验性高脂血症兔降血脂的作用。方法：选择普通级新西兰家兔 60 只,雌雄不限,随机挑选 7 只作正常对照组,普通饲料饲养;其余家兔制作高脂血症模型,高脂饲粒饲养1 个月后,将总胆固醇（TC）水平过高和过低的家兔11只除外,剩余 42 只家兔随机平均分为模型组,脂汰清高、中、低剂量组,辛伐他汀组,山楂精降脂组,每组 7 只,改喂普通饲料。正常组和模型组动物以成人药量脂汰清胶囊溶于10 m L 蒸馏水注射;辛伐他汀组以3 倍成人药量的辛伐他汀 ＋ 阿拉伯树胶溶于 10 m L 蒸馏水中注射;山楂精降脂组以 3 倍成人药量山楂精降脂片 ＋ 阿拉伯树胶溶于 10 m L 蒸馏水中注射;脂汰清高、中、低剂量组分别以成人量 6 倍（0.72 g·kg^-1）、3 倍（0.36 g· kg^-1）、1 倍（0.12 g kg 1）＋ 阿拉伯树胶溶于 10 m L 蒸馏水注射。用酶法及免疫透射比浊法检测血清 TC、三酰甘油（TG）、高密度脂蛋白（H DL）、低密度脂蛋白（LDL）。严格按试剂盒工作。结果：与治疗前比较,各给药组 TC、TG、H DL 明显改善,差异有统计学意义（P 〈 0.05）,与辛伐他汀组、山楂精降脂组相比,脂汰清各组各指标改善明显,差异有统计学意义（P 〈 0.05）。各组治疗前后 LDL 变化不大,差异无统计学意义（P 〉 0.05）。结论：脂汰清对高脂血症兔具有明显的降血脂作用。     

银杏叶提取物对大鼠高脂血症的影响

目的:研究银杏叶提取物(EGb761)对高脂血症大鼠血脂的影响及机制.方法:雄性SD大鼠高脂饲养4周诱发高脂血症,其中实验组在高脂饲料饲养2周后开始每日灌胃给予EGb761(1.0g/kg),持续2周.实验结束后,颈动脉取血测定血脂、一氧化氮(NO)、非对称二甲基精氨酸(ADMA)和丙二醛(MDA)含量.结果:EGb761能显著降低高脂血症大鼠血清总胆固醇和低密度脂蛋白及甘油三酯水平.EGb761能显著降低血浆ADMA和MDA含量以及增加NO水平.结论:银杏叶提取物EGb761具有降低血脂,其作用与抑制脂质过氧化、调节ADMA/NO系统有关.     

化痰降浊汤对高脂血症血脂的影响

目的观察化痰降浊汤对高脂血症患者血脂的影响。方法选取60例患者,予化痰降浊汤口服(药物组成:泽泻15 g,山楂10 g,陈皮20 g。水煎取汁150 mL。消毒,灭菌,4℃保存备用),1次/d,连续30 d。结果服用化痰降浊汤后,总胆固醇、三酰甘油、低密度脂蛋白胆固醇指标均下降,高密度脂蛋白胆固醇指标上调。结论化痰降浊汤具有调节血脂的作用。     

不同配方高脂乳剂大鼠高脂血症模型的研究

目的:探讨6种不同配方高脂乳剂对大鼠高脂血症形成时间、程度及恢复情况的影响。方法:采用连续灌服不同配方高脂乳剂的方法,分别于2周、4周及停止灌服高脂乳剂后2周大鼠眼底静脉丛、腹主动脉采血检测总胆固醇(TC)、甘油三脂(GT)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)血脂4项指标。结果:灌服高脂乳剂2周后,2号、3号及6号配方大鼠TC、LDL显著升高,与空白对照组比较差异显著(P﹤0.05,P﹤0.001),其中6号配方乳剂大鼠GT也明显升高,与空白对照组比较差异显著(P﹤0.05);灌服高脂乳剂4周后,1号、2号、3号及6号配方大鼠TC、GT、LDL显著升高,与空白对照组比较差异显著(P﹤0.05,P﹤0.01,P﹤0.001),但HDL没有明显变化;而4号、5号配方大鼠TC、GT、HDL均没有明显改变,与空白对照组比较无显著性差异(P>0.05),只有LDL显著升高;各组大鼠停止灌服高脂乳剂2周后,大鼠TC、GT、LDL均显著降低,与空白对照组比较没有显著性差异(P>0.05),已达到正常范围。结论:由猪油(15%)、胆固醇(2.5%)、蛋黄粉(2.5%)、丙硫氧嘧啶(0.5%)、吐温-80(1%)、蒸馏水(78.5%)组成的2号,由猪油(15%)、胆固醇(2.5%)、蛋黄粉(2.5%)、葡萄糖(5%)、吐温-80(1%)、蒸馏水(74%)组成的3号,由猪油(15%)、胆固醇(2.5%)、蛋黄粉(2.5%)、猪胆酸钠(0.5%)、丙硫氧嘧啶(0.25%)、葡萄糖(2.5%)、吐温-80(1%)、蒸馏水(75.75%)组成的6号高脂乳剂配方在2周内即可造成大鼠高脂血症;由猪油(15%)、胆固醇(2.5%)、蛋黄粉(2.5%)、猪胆酸钠(1%)、吐温-80(1%)、蒸馏水(78%)组成的1号高脂乳剂配方在4周内可造成大鼠高脂血症;而由猪油(15%)、胆固醇(2.5%)、蛋黄粉(2.5%)、吐温-80(1%)、蒸馏水(79%)组成的4号,由猪油(15%)、胆固醇(2.5%)、吐温-80(1%)、蒸馏水(81.5%)组成的5号高脂乳剂配方在4周内未造成大鼠高脂血症;大鼠灌服各高脂乳剂造成的高脂血症在2周内可恢复正常。     

女贞叶乙醇提取物对鹌鹑高脂血症的影响

目的:观察女贞叶乙醇提取物对鹌鹑高脂血症的影响.方法:用外源性胆固醇和高脂饲料复制鹌鹑高脂血症模型,并诱发其肝脂肪变性,分为正常对照组、高脂模型组、脂必妥组(3 g·kg-1)、女贞叶乙醇提取物高、中、低组(1.5,3,6g·kg-1),给药4周.分别测定各组血清甘油三酯(TG)、胆固醇(CHO)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)的含量,并进行鹌鹑肝脂肪变性的病理组织学检查.结果:女贞叶乙醇提取物低剂量能降低血清TG(P ＜0.05);中、高剂量能明显降低血清TG,CHO(P ＜0.01),中、高剂量降低血清LDL-C(P＜0.05,P＜0.01),高剂量组能明显升高血清HDLC(P＜0.01).给予女贞叶乙醇提取物后,鹌鹑肝系数明显减轻(P＜0.01),肝中脂肪空泡数明显减少(P＜0.01).结论:女贞叶乙醇提取物具有明显的防治鹌鹑高脂血症和肝脂肪变性的作用.     

Effect of Momordica charantia on lipid profile and oral glucose tolerance in diabetic rats

In this study, the methanol extract of Momordica charantia fruit extract was administered to diabetic rats to assess the long term effect of the extract on the lipid profile and the oral glucose tolerance test. Treatment for 30 days showed a significant decrease in triglyceride, low density lipoprotein and a significant increase in high density lipoprotein level. A significant effect on oral glucose tolerance was also noted. Chronic administration showed an improvement in the oral glucose tolerance curve. The effect was more pronounced when the test was done in rats fed the extract on the day of the test compared with tests done in rats which were not fed the extract on the same day.     

Effect of purslane on blood lipids and glucose: A systematic review and meta‐analysis of randomized controlled trials

Despite a history of purslane usage as a herbal treatment for dyslipidemia and hyperglycemia management, existing evidence from clinical trials is controversial. The aim for the current study was to evaluate the efficacy of purslane supplementation on lipid parameters and glycemic status in adult populations. A systematic review was conducted in PubMed, Scopus, ISI Web of Science, and Google Scholar up to January 15, 2018, searching for randomized controlled trials that assessed the impact of purslane on fasting blood glucose (FBG), triglycerides, total cholesterol (TC), low‐density lipoprotein cholesterol (LDL‐C), and high‐density lipoprotein cholesterol (HDL‐C). Based on the detected heterogeneity between studies, a random‐ or fixed‐effect model was applied in the meta‐analysis. The findings from six randomized controlled trials, comprising 352 participants, indicated that purslane can reduce FBG (?4.54 mg/dl, 95% CI [?7.54, ?1.53]; I² = 0.53%) and triglycerides (?19.16 mg/dl, 95% CI [?38.17, ?0.15]; I² = 0%) levels. Changes in TC, LDL‐C, and HDL‐C concentrations did not reach a statistically significant level. Subgroup analysis showed a favorable effects of purslane on FBG, triglycerides, TC, and LDL‐C in a subset of studies in which purslane was administered >1.5 g/day. Categorization based on gender showed that purslane was more effective in improving FBG, TC and LDL‐C in females compared with males. This systematic review and meta‐analysis suggested that the purslane might be effective on the improvement of blood lipid and glucose levels. Further robust studies with sufficient durations and dosages of supplementation are needed to confirm these results.     

The impact of argan oil on plasma lipids in humans: Systematic review and meta‐analysis of randomized controlled trials

The study aims to investigate the effect of argan oil on plasma lipid concentrations through a systematic review of the literature and a meta‐analysis of available randomized controlled trials. Randomized controlled trials that investigated the impact of at least 2 weeks of supplementation with argan oil on plasma/serum concentrations of at least 1 of the main lipid parameters were eligible for inclusion. Effect size was expressed as the weighted mean difference (WMD) and 95% confidence interval (95% CI). Meta‐analysis of data from 5 eligible trials with 292 participants showed a significant reduction in plasma concentrations of total cholesterol (WMD: ?16.85 mg/dl, 95% CI [?25.10, ?8.60], p < .001), low‐density lipoprotein cholesterol (WMD: ?11.67 mg/dl, 95% CI [?17.32, ?6.01], p < .001), and triglycerides (WMD: ?13.69 mg/dl, 95% CI [?25.80, ?1.58], p = .027) after supplementation with argan oil compared with control treatment, and plasma concentrations of high‐density lipoprotein cholesterol (WMD: 4.14 mg/dl, 95% CI [0.86, 7.41], p = .013) were found to be increased. Argan oil supplementation reduces total cholesterol, low‐density lipoprotein cholesterol, and triglycerides and increases high‐density lipoprotein cholesterol levels. Additionally, larger clinical trials are needed to assess the impact of argan oil supplementation on other indices of cardiometabolic risk and on the risk of cardiovascular outcomes.     

Effects of silymarin supplementation on blood lipids: A systematic review and meta‐analysis of clinical trials

Dyslipidemia is a leading cause of endothelial dysfunction and cardiovascular disease. Several studies used silymarin as an herbal supplement in hyperlipidemic subjects. The aim of the present systematic review and meta‐analysis was to examine the effect of silymarin supplementation on blood lipids. PubMed, Scopus, Ovid (Cochrane library), ISI Web of Science, and Google Scholar were systematically searched until March 2018 to find intervention studies that examined the impact of silymarin supplementation on blood lipids in adults. Changes in blood lipids and potential sources of between‐study variation were extracted. We run a subgroup analysis to determine potential sources of inter‐study heterogeneity. Ten clinical trials fulfilled the eligibility criteria. Meta‐analysis indicated that silymarin supplementation in combination with other treatments (not silymarin alone) reduced total cholesterol (change: ?25.45 mg/dl; 95% confidence interval [CI] [?47.89, ?3.01 mg/dl]) and low‐density lipoprotein (change: ?28.25 mg/dl; 95% CI [?53.09, ?3.42 mg/dl]). Also, silymarin increased high‐density lipoprotein concentration (change: 4.82 mg/dl; 95% CI [2.01, 7.63 mg/dl]). Blood concentration of triglyceride was significantly after silymarin supplementation in comparison with controls (change: ?22.55 mg/dl; 95% CI [?44.32, ?0.78 mg/dl]). Present systematic review and meta‐analysis revealed that silymarin supplementation in combination with other treatments had a favorable effect on blood lipids.